{mosads}Specifically, Pitts and Burgess said they want to look at incentives for biologics, the integrity of the drug supply chain and and the FDA’s broader attitude toward innovation.
They suggested establishing a panel similar to the Medicare Payment Advisory Commission that would advise FDA on bettering its performance.
Energy and Commerce has focused all week on health information technology, another priority.
Several GOP members have warned that the current regulatory environment could threaten the development of mobile health apps — a claim Democrats deny.